Overview
A serotonin-noradrenaline-dopamine reuptake inhibitor initially developed for Alzheimer's and Parkinson's disease. Clinical trials revealed significant weight loss effects, shifting research focus to obesity treatment.
Benefits
- ✓weight loss support
- ✓appetite suppression
- ✓metabolic enhancement
- ✓energy and focus
Potential Side Effects
- •dry mouth
- •nausea
- •diarrhea
- •insomnia
- •increased heart rate
- •elevated blood pressure
- •anxiety or mood changes
Who Should Avoid
- ⚠pregnancy or breastfeeding
- ⚠cardiovascular disease or uncontrolled hypertension
- ⚠history of eating disorders
- ⚠severe anxiety or psychiatric conditions
- ⚠concurrent use of MAO inhibitors or other psychiatric medications
Interactions & Precautions
CRITICAL: Significant interaction risk with antidepressants (SSRIs, SNRIs), MAO inhibitors, stimulants, and blood pressure medications. Can cause serotonin syndrome. Comprehensive psychiatric and cardiovascular evaluation mandatory before use.
Dosing Information from Literature
Clinical trials for obesity explored doses of 0.25-1 mg per day orally. The 0.5 mg dose showed optimal efficacy-to-safety ratio in phase 2 trials. Not approved for use in most countries.
This is descriptive information only. Always consult a licensed healthcare provider for dosing guidance.
Storage
Store in cool, dry place away from light. Follow specific product storage instructions as this is typically an oral compound.